ClinicalTrials.gg
RecruitingNCT05886205Updated Jun 7, 2023

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Refractory Focal Epilepsy

An Early Phase 1 interventional study of iPSC-Exos in Refractory Focal Epilepsy, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-06-07.

Sponsored by Peking Union Medical College Hospital · Early Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
34
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Epilepsies, Partial with a site in China — 6 open to participants now, 6 under way, none of them phase 3. Epilepsies, Partial · China.

Started
2023
the only one that year
Phase 1
Only one
of the 10
Registered
3rd of 10
by date
Lead sponsor
1 of 10
Peking Union Medical College Hospital

Among the 10 studies in Epilepsies, Partial with a site in China, this one is the only one that started in 2023, is the only one in phase 1, and was the 3rd registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

6 of the 10 studies in Epilepsies, Partial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Epilepsies, Partial with a site in China, or all of them as a file.
02

Study summary

Evaluate the safety, tolerability, and preliminary efficacy of GD-iEXo-002 nasal drops in the treatment of focal refractory epilepsy

Read the detailed description

Epilepsy patients can achieve good control after treatment, but still 30% of patients are medically refractory epilepsy, with the vast majority being focal epilepsy. Recurrent seizures seriously affect the normal development, learning, and life of patients. There is an urgent need for effective drugs to treat refractory focal epilepsy in clinical practice.

Exosomes are a kind of vesicle structures secreted by cells, with a diameter of 30-150 nm, carrying proteins, nucleic acids and other substances. Exosomes have many advantages. As naturally occurring nanoscale secretory membrane vesicles, they have extremely low immunogenicity and good safety, and can cross biological barriers such as the blood-brain barrier and the blood-tumor barrier. Exosomes have specific bioactive substances related to source cells, while stem cell exosomes contain TGF- β、 Functional factors such as BDNF can inhibit cell apoptosis, inhibit inflammatory response, promote angiogenesis, inhibit fibrosis, and enhance tissue repair potential, with a wide range of potential applications.

Induced pluripotent stem cell (iPSC) originates from single cell amplification, with infinite proliferation ability, good consistency and stability; MSCs exhibit significant heterogeneity.

The purpose of this single center, open label clinical trial is to evaluate the safety, tolerability, and preliminary efficacy of induced pluripotent stem cell derived exosomes (iPSC-Exos) nasal drops in the treatment of focal refractory epilepsy.

03

Conditions studied

  • Refractory Focal Epilepsy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before conducting this study, understand and sign the form and comply with the requirements of this study;
  2. The subjects are patients with focal epilepsy aged 18 to 70 years (inclusive), regardless of gender;
  3. The subjects must comply with the definition of drug resistant epilepsy (ILAE);
  4. Subjects must take 1-6 types of anti-epileptic drugs (AEDs), and before entering the screening period, they must take unadjusted types and stable doses of AEDs for at least 4 weeks;
  5. Throughout the entire research process, the subject/legal guardian must be able to accurately record the log of epileptic seizures;
  6. Subjects must experience at least 4 countable seizures within 28 days prior to the screening period;
  7. The subjects are willing and able to comply with the research requirements.

Exclusion criteria

Exclusion Criteria:

  1. Unwilling or unable to follow the procedures stipulated in the agreement;
  2. Pregnant or lactating women, or women with who are unable or unwilling to take appropriate measures;
  3. Other uncontrollable diseases that may interfere with the research results, including but not limited to infection, hypertension, diabetes, cardiovascular and cerebrovascular diseases, etc;
  4. There are situations that may increase the risk of participating in experiments or research product use, such as liver enzyme elevation exceeding twice the normal upper limit and/or \<60 mL/min/1.73 m2;
  5. Have a history of drug abuse, alcohol dependence, or smoking within one month;
  6. Patients with status epilepticus within one month;
  7. Have potential progressive nervous system disease, such as encephalitis, brain tumor, multiple sclerosis or dementia;
  8. Patients who plan to undergo epilepsy surgery within six months;
  9. Patients with abnormal or diseased nasal structures;
  10. Patients with cerebrospinal fluid rhinorrhea;
  11. Patients whose family members have not been able to proficiently and correctly master the nasal drip method through standardized training
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    iPSC-exosome treatment

    group1-low-dose group, 8 papatients are treated with 2 μg iPSC-Exos in 200 μL. group2-mid-dose group, 8 papatients are treated with 6 μg iPSC-Exos in 200 μL. group3-mid-dose group, 8 papatients are treated with 18 μg iPSC-Exos in 200 μL. group4-Dose expansion, 10 papatients are treated with iPSC-Exos in 200 μL. iPSC-Exos were administrated for nasal drip, bid for 12 weeks.

    Drug: iPSC-Exos

Interventions

  • DrugiPSC-Exos

    iPSC-Exos were administrated for nasal drip, bid for 12 weeks.

06

What researchers measure

Primary outcomes

  1. adverse events as assessed by CTCAE

    all potentially treated subjects to assess the safety

    Time frame: 24 weeks from post-administration

Secondary outcomes

  1. Number of participants with abnormal vital signs and abnormal Physical examination findings

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

  2. Number of participants with abnormal Neurological examination

    Evaluate general neurological status, muscle strength and tension, sensory ataxia, and pathological signs

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

  3. Number of participants with abnormal laboratory tests results

    Blood routine test, blood biochemistry test ,and electrolytes test

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

  4. Number of participants with abnormal Urine analysis

    Urine routine examination

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

  5. Seizures frequency

    Seizure frequency: i. no seizures: any type of seizure disappeared after 28 days of observation; ii. significantly effective: 75%-99% reduction in seizure frequency compared with baseline; iii. Effective: 50%-75% reduction in seizure frequency compared with baseline; iv. Improvement: 25%-50% reduction in the number of seizures compared with baseline, or prolongation, reduction in degree, and shortening of duration between episodes; v. Ineffectiveness and exacerbation: Ineffectiveness refers to a decrease or increase of \<25% in the number of seizures compared with baseline, and exacerbation refers to an increase in the frequency of seizures from baseline ≥25%.

    Time frame: before administration; administration; after the first administration 1 week,2 weeks,4 weeks,8 weeks,12 weeks,16 weeks,24 weeks

  6. Scalp electroencephalogram monitoring

    Time frame: Screening, after the first administration 12 weeks

  7. Head magnetic resonance imaging (MRI) examination

    Time frame: Screening, after the first administration 12 weeks

Other outcomes

  1. Exploratory research-1

    The protein concentration of GFAP, IL-1 β、 IL-6、IL-10、IL-17a、TGF- β、 MCP-1 and TNF- α in blood

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

  2. Exploratory research-2

    T cell, B cell, NK cell subpopulation analysis

    Time frame: Screening, after the first administration 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 24 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2023; primary completion for Jun 2025, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2023
First posted
Jun 2, 2023
StartEst.
Jun 5, 2023
Primary completionEst.
Jun 13, 2025
CompletionEst.
Nov 13, 2025
Last update
Jun 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05886205
Collaborators
Guidon Pharmaceutics Ltd.
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Jun 5, 2023 (estimated)
Primary completion
Jun 13, 2025 (estimated)
Completion
Nov 13, 2025 (estimated)
Last update
Jun 7, 2023

Study contacts

Xue Zhao
Contact
zhaoxue_pumch@sina.com
+8601069154786
Xiaohong Han
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion